Bay City Capital Fund V Co-Investment Fund, L.P.
CIK 0001409813 Name as filed on the most recent filing
Filed as Bay City Capital Fund V Co-Investment Fund, L.P. (13)· Bay City Capital Fund V Co-Investment Fund LP (1)
46 transaction lines · from 14 filings · filed 2010-07-01 to 2016-08-02 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER Interleukin Genetics Inc 2 filings
- ISSUER Epizyme, Inc. 5 filings
- ISSUER Sunesis Pharmaceuticals Inc 4 filings
- ISSUER Dermira, Inc. 1 filings
- ISSUER Hyperion Therapeutics Inc 2 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2016-07-29 |
Interleukin Genetics Inc ILIU |
P, Open-market purchase | 29,616,700 acquired | 0.10 | 2,943,899.98 | Form 4, filing 0000899243-16-026077 | |
| 2016-07-29 |
Interleukin Genetics Inc ILIU |
P, Open-market purchase | 564,386 acquired | 0.10 | 56,099.97 | Form 4, filing 0000899243-16-026077 | |
| 2016-01-12 |
Epizyme, Inc. EPZM |
P, Open-market purchase | 545,166 acquired | 9.00 | 4,906,494.00 | Form 4, filing 0001209191-16-090962 | |
| 2016-01-12 |
Epizyme, Inc. EPZM |
P, Open-market purchase | 10,389 acquired | 9.00 | 93,501.00 | Form 4, filing 0001209191-16-090962 | |
| 2015-07-24 |
Sunesis Pharmaceuticals Inc SNSS |
S, Open-market sale | 415,877 disposed | 3.46 | 1,438,934.42 | Form 4, filing 0000899243-15-001801 | |
| 2015-07-24 |
Sunesis Pharmaceuticals Inc SNSS |
S, Open-market sale | 207,938 disposed | 3.46 | 719,465.48 | Form 4, filing 0000899243-15-001801 | |
| 2015-07-24 |
Sunesis Pharmaceuticals Inc SNSS |
S, Open-market sale | 7,925 disposed | 3.46 | 27,420.50 | Form 4, filing 0000899243-15-001801 | |
| 2015-07-24 |
Sunesis Pharmaceuticals Inc SNSS |
S, Open-market sale | 3,962 disposed | 3.46 | 13,708.52 | Form 4, filing 0000899243-15-001801 | |
| 2014-12-23 |
Interleukin Genetics Inc ILIU |
P, Open-market purchase | 25,996,552 acquired | 0.10 | 2,607,454.17 | Form 4, filing 0001209191-14-077958 | |
| 2014-12-23 |
Interleukin Genetics Inc ILIU |
P, Open-market purchase | 495,400 acquired | 0.10 | 49,688.62 | Form 4, filing 0001209191-14-077958 | |
| 2014-10-08 |
Dermira, Inc. DERM |
P, Open-market purchase | 67,820 acquired | 16.00 | 1,085,120.00 | Form 4, filing 0001140361-14-037654 | |
| 2014-10-08 |
Dermira, Inc. DERM |
P, Open-market purchase | 1,292 acquired | 16.00 | 20,672.00 | Form 4, filing 0001140361-14-037654 | |
| 2014-08-28 |
Sunesis Pharmaceuticals Inc SNSS |
S, Open-market sale | 196,260 disposed | 7.89 | 1,547,529.73 | Form 4, filing 0001181431-14-030525 | |
| 2014-08-28 |
Sunesis Pharmaceuticals Inc SNSS |
S, Open-market sale | 3,740 disposed | 7.89 | 29,490.27 | Form 4, filing 0001181431-14-030525 | |
| 2014-08-27 |
Sunesis Pharmaceuticals Inc SNSS |
S, Open-market sale | 98,817 disposed | 8.16 | 806,643.17 | Form 4, filing 0001181431-14-030525 | |
| 2014-08-27 |
Sunesis Pharmaceuticals Inc SNSS |
S, Open-market sale | 1,883 disposed | 8.16 | 15,370.93 | Form 4, filing 0001181431-14-030525 | |
| 2014-08-26 |
Epizyme, Inc. EPZM |
S, Open-market sale | 196,260 disposed | 35.14 | 6,896,380.14 | Form 4, filing 0001209191-14-054864 | |
| 2014-08-26 |
Epizyme, Inc. EPZM |
S, Open-market sale | 3,740 disposed | 35.14 | 131,419.86 | Form 4, filing 0001209191-14-054864 | |
| 2014-08-25 |
Epizyme, Inc. EPZM |
S, Open-market sale | 195,377 disposed | 35.13 | 6,864,238.75 | Form 4, filing 0001209191-14-054308 | |
| 2014-08-25 |
Epizyme, Inc. EPZM |
S, Open-market sale | 3,723 disposed | 35.13 | 130,801.28 | Form 4, filing 0001209191-14-054308 | |
| 2014-08-25 |
Epizyme, Inc. EPZM |
S, Open-market sale | 883 disposed | 36.40 | 32,143.67 | Form 4, filing 0001209191-14-054308 | |
| 2014-08-25 |
Epizyme, Inc. EPZM |
S, Open-market sale | 17 disposed | 36.40 | 618.85 | Form 4, filing 0001209191-14-054308 | |
| 2014-08-22 |
Epizyme, Inc. EPZM |
S, Open-market sale | 125,606 disposed | 32.46 | 4,077,057.71 | Form 4, filing 0001209191-14-054308 | |
| 2014-08-22 |
Epizyme, Inc. EPZM |
S, Open-market sale | 2,394 disposed | 32.46 | 77,707.09 | Form 4, filing 0001209191-14-054308 | |
| 2014-08-21 |
Epizyme, Inc. EPZM |
S, Open-market sale | 37,943 disposed | 33.04 | 1,253,454.59 | Form 4, filing 0001209191-14-054308 | |
| 2014-08-21 |
Epizyme, Inc. EPZM |
S, Open-market sale | 723 disposed | 33.04 | 23,884.45 | Form 4, filing 0001209191-14-054308 | |
| 2014-08-12 |
Sunesis Pharmaceuticals Inc SNSS |
S, Open-market sale | 36,406 disposed | 6.77 | 246,530.51 | Form 4, filing 0001181431-14-029004 | |
| 2014-08-12 |
Sunesis Pharmaceuticals Inc SNSS |
S, Open-market sale | 694 disposed | 6.77 | 4,699.56 | Form 4, filing 0001181431-14-029004 | |
| 2014-08-11 |
Sunesis Pharmaceuticals Inc SNSS |
S, Open-market sale | 31,009 disposed | 6.90 | 214,024.12 | Form 4, filing 0001181431-14-029004 | |
| 2014-08-11 |
Sunesis Pharmaceuticals Inc SNSS |
S, Open-market sale | 591 disposed | 6.90 | 4,079.08 | Form 4, filing 0001181431-14-029004 | |
| 2014-08-08 |
Sunesis Pharmaceuticals Inc SNSS |
S, Open-market sale | 662,378 disposed | 6.62 | 4,385,008.60 | Form 4, filing 0001181431-14-029004 | |
| 2014-08-08 |
Sunesis Pharmaceuticals Inc SNSS |
S, Open-market sale | 12,622 disposed | 6.62 | 83,558.90 | Form 4, filing 0001181431-14-029004 | |
| 2014-02-10 |
Epizyme, Inc. EPZM |
S, Open-market sale | 457,940 disposed | 29.25 | 13,394,745.00 | Form 4, filing 0001209191-14-009595 | |
| 2014-02-10 |
Epizyme, Inc. EPZM |
S, Open-market sale | 8,727 disposed | 29.25 | 255,264.75 | Form 4, filing 0001209191-14-009595 | |
| 2013-06-05 |
Epizyme, Inc. EPZM |
P, Open-market purchase | 163,549 acquired | 15.00 | 2,453,235.00 | Form 4, filing 0001209191-13-031138 | |
| 2013-06-05 |
Epizyme, Inc. EPZM |
P, Open-market purchase | 3,117 acquired | 15.00 | 46,755.00 | Form 4, filing 0001209191-13-031138 | |
| 2013-05-30 |
Hyperion Therapeutics Inc HPTX |
S, Open-market sale | 5,266 disposed | 21.00 | 110,586.00 | Form 4, filing 0001181431-13-031712 | |
| 2013-05-30 |
Hyperion Therapeutics Inc HPTX |
S, Open-market sale | 100 disposed | 21.00 | 2,100.00 | Form 4, filing 0001181431-13-031712 | |
| 2013-05-28 |
Hyperion Therapeutics Inc HPTX |
S, Open-market sale | 11,776 disposed | 21.08 | 248,238.08 | Form 4, filing 0001181431-13-031712 | |
| 2013-05-28 |
Hyperion Therapeutics Inc HPTX |
S, Open-market sale | 224 disposed | 21.08 | 4,721.92 | Form 4, filing 0001181431-13-031712 | |
| 2013-05-20 |
Hyperion Therapeutics Inc HPTX |
S, Open-market sale | 1,963 disposed | 22.24 | 43,657.12 | Form 4, filing 0001181431-13-029568 | |
| 2013-05-20 |
Hyperion Therapeutics Inc HPTX |
S, Open-market sale | 37 disposed | 22.24 | 822.88 | Form 4, filing 0001181431-13-029568 | |
| 2013-05-17 |
Hyperion Therapeutics Inc HPTX |
S, Open-market sale | 127,034 disposed | 22.69 | 2,882,401.46 | Form 4, filing 0001181431-13-029568 | |
| 2013-05-17 |
Hyperion Therapeutics Inc HPTX |
S, Open-market sale | 2,421 disposed | 22.69 | 54,932.49 | Form 4, filing 0001181431-13-029568 | |
| 2010-06-30 |
Sunesis Pharmaceuticals Inc SNSS |
P, Open-market purchase | 23,378,934 acquired | 0.28 | 6,429,206.85 | Form 4, filing 0001209191-10-036694 | |
| 2010-06-30 |
Sunesis Pharmaceuticals Inc SNSS |
P, Open-market purchase | 445,516 acquired | 0.28 | 122,516.90 | Form 4, filing 0001209191-10-036694 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
- S, Open-market sale
- Open-market sale
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Bay City Capital Fund V Co-Investment Fund, L.P., insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001409813
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6